Europe's Insured Losses Are Climbing as Catastrophes, Inflation and Construction Costs Combine, Verisk Finds
Source: globenewswire.com

Verisk’s 2026 Global Modelled Catastrophe Losses Report forecasts the insurance industry should be prepared for $171B in average insured catastrophe losses per year, up $19B year over year (highest estimate to date). The increase persists despite no U.S. hurricane landfalls for the first time in a decade, implying higher loss benchmarks driven by rising property/insured values globally, which may raise insurers’ risk and underwriting caution.
Analysis
This is more of a pricing signal than a standalone earnings catalyst. The immediate losers are cat-exposed P&C carriers and reinsurers because higher modeled losses widen the gap between current premium levels and the capital they need to earn an acceptable return; that gap typically shows up first in 1/1 renewal negotiations and reinsurance attachment points, then leaks into 2027 combined ratios. The relative winners are the data/tollbooth businesses and anyone who earns fees as complexity rises: VRSK should be structurally sticky, while brokers and alternative capital managers can gain flow as traditional reinsurance becomes more expensive.
The second-order effect is portfolio reshuffling, not instant industry pain. Expect capital to migrate away from the most catastrophe-intensive books and toward diversified insurers with lower coastal concentration, while brokers see more demand for layered coverage and cat bonds as buyers seek capacity. That creates a slower-burn outperformance path for diversified names versus pure-play homeowners/specialty underwriters over the next 1-3 renewal cycles.
Contrarianly, the market may already treat rising modeled losses as background noise tied to replacement-cost inflation, so the stock-level reaction can be muted unless actual loss experience or renewal pricing accelerates. The key falsifier is simple: if 1/1 reinsurance and primary rate filings do not firm despite the higher benchmark, the thesis is mostly noise. Conversely, if spread widening in cat bonds and reserve strengthening start to appear, the signal becomes actionable for 6-18 months.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
Key Decisions for Investors
- Long VRSK / short KIE into the 1/1 renewal setup: use this as a relative-value expression that catastrophe complexity stays monetizable while cat-heavy insurers face higher capital drag. Best risk/reward if the spread is entered on any market weakness; thesis breaks if renewal pricing softens or VRSK guidance implies no incremental wallet share.
- Short KIE or IAK on rallies over the next 1-3 months, targeting insurers/reinsurers with the highest coastal catastrophe concentration. This is a cleaner sector expression than single-name shorts; cover if the ETF re-rates to reflect stronger-than-expected rate increases or benign actual cat losses.
- Prefer diversified property/casualty platforms over cat-intensive names for 6-18 months; within the sector, favor names with lower Florida/California dependence and stronger fee/placement franchises. The relative winner set should include brokers and broad-based carriers, not pure homeowners books.
- Set a watch item on cat bond spreads and 1/1 reinsurance renewal commentary. If spreads widen materially or ceded reinsurance costs rise faster than premium growth, increase the short in KIE/IAK; if not, assume the report is mostly a sentiment event and fade the move.
More News
- One Singapore ship was sunk, but here's why others are still transiting the Strait of Hormuz
- Order to limit Starshield for Ukraine came from inside White House: Reuters reports
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- BOE Chief Says Energy Shock Delays 2% Inflation Target
- FDA approves Enspryng for thyroid eye disease treatment